PMID- 36139561
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 18
DP  - 2022 Sep 10
TI  - From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of 
      Antiepileptic Drugs Repositioning in Cancer.
LID - 10.3390/cancers14184401 [doi]
LID - 4401
AB  - Cancer is a major health burden worldwide. Although the plethora of molecular 
      targets identified in the last decades and the deriving developed treatments, 
      which significantly improved patients' outcome, the occurrence of resistance to 
      therapies remains the major cause of relapse and mortality. Thus, efforts in 
      identifying new markers to be exploited as molecular targets in cancer therapy 
      are needed. This review will first give a glance on the diagnostic and 
      therapeutic significance of histone deacetylase (HDAC) and voltage gated ion 
      channels (VGICs) in cancer. Nevertheless, HDAC and VGICs have also been reported 
      as molecular targets through which antiepileptic drugs (AEDs) seem to exert their 
      anticancer activity. This should be claimed as a great advantage. Indeed, due to 
      the slowness of drug approval procedures, the attempt to turn to off-label use of 
      already approved medicines would be highly preferable. Therefore, an updated and 
      accurate overview of both preclinical and clinical data of commonly prescribed 
      AEDs (mainly valproic acid, lamotrigine, carbamazepine, phenytoin and gabapentin) 
      in breast, prostate, brain and other cancers will follow. Finally, a glance at 
      the emerging attempt to administer AEDs by means of opportunely designed drug 
      delivery systems (DDSs), so to limit toxicity and improve bioavailability, is 
      also given.
FAU - Pellegrino, Michele
AU  - Pellegrino M
AD  - Department of Pharmacy and Health and Nutritional Sciences, University of 
      Calabria, 87036 Rende, Italy.
FAU - Ricci, Elena
AU  - Ricci E
AD  - Department of Pharmacy and Health and Nutritional Sciences, University of 
      Calabria, 87036 Rende, Italy.
FAU - Ceraldi, Rosangela
AU  - Ceraldi R
AD  - Department of Pharmacy and Health and Nutritional Sciences, University of 
      Calabria, 87036 Rende, Italy.
FAU - Nigro, Alessandra
AU  - Nigro A
AD  - Department of Pharmacy and Health and Nutritional Sciences, University of 
      Calabria, 87036 Rende, Italy.
FAU - Bonofiglio, Daniela
AU  - Bonofiglio D
AUID- ORCID: 0000-0002-4142-0496
AD  - Department of Pharmacy and Health and Nutritional Sciences, University of 
      Calabria, 87036 Rende, Italy.
FAU - Lanzino, Marilena
AU  - Lanzino M
AD  - Department of Pharmacy and Health and Nutritional Sciences, University of 
      Calabria, 87036 Rende, Italy.
FAU - Morelli, Catia
AU  - Morelli C
AUID- ORCID: 0000-0002-9407-0805
AD  - Department of Pharmacy and Health and Nutritional Sciences, University of 
      Calabria, 87036 Rende, Italy.
LA  - eng
GR  - Department of Excellence (MIUR, Italian Law 232/2016), granted to the Department 
      of Pharmacy, and the Health and Nutritional Sciences, University of Calabria, 
      Italy/Ministry of Education, Universities and Research/
GR  - POR Calabria FESR-FSE 2014/2020-Axis 12, Actions 10.5.6 and 10.5.12 
      "International mobility of PhD students"/Ministry of Education, Universities and 
      Research/
PT  - Journal Article
PT  - Review
DEP - 20220910
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9497059
OTO - NOTNLM
OT  - HDAC inhibitors
OT  - adjuvant anti-cancer therapy
OT  - antiepileptic drugs
OT  - cancer
OT  - carbamazepine
OT  - drug repositioning
OT  - gabapentin
OT  - lamotrigine
OT  - phenytoin
OT  - valproic acid
OT  - voltage gated calcium channels
OT  - voltage gated sodium channels
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/09/10
CRDT- 2022/09/23 01:07
PHST- 2022/08/04 00:00 [received]
PHST- 2022/09/02 00:00 [revised]
PHST- 2022/09/03 00:00 [accepted]
PHST- 2022/09/23 01:07 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/09/10 00:00 [pmc-release]
AID - cancers14184401 [pii]
AID - cancers-14-04401 [pii]
AID - 10.3390/cancers14184401 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Sep 10;14(18):4401. doi: 10.3390/cancers14184401.